Madison Vaccines’ backers have injected around $2 million more into the startup to help advance three clinical trials of its experimental DNA vaccines that aim to treat prostate cancer.
The Madison, WI-based drug developer today announced an expansion of its Series A funding round, upping the total from more than $9 million to $11 million, Madison Vaccines co-founder, president, and CEO Rick Lesniewski told Xconomy. The additional money comes from previous investors, including Venture Investors, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board, and Venture Management, all based in Madison.
Read more at Xconomy.